Seroprevalence of Alphaviruses (Togaviridae) among Urban Population in Nouakchott, Mauritania, West Africa

Viruses. 2023 Jul 20;15(7):1588. doi: 10.3390/v15071588.

Abstract

The presence of alphaviruses, such as chikungunya virus (CHIKV), has never been reported in Mauritania. We assessed the seroprevalence of CHIKV among Nouakchott residents. A cross-sectional study involving 1300 non-febrile patients consulting at the Nouakchott hospital center was conducted between January and June 2021. The presence of anti-CHIKV IgG and neutralizing antibodies against CHIKV, O'nyong-nyong virus (ONNV), and Semliki Forest virus (SFV) was determined by an enzyme-linked immunosorbent assay (ELISA) and a serum neutralization test, respectively, and the associated risk factors were investigated. Of the 1300 study participants, serological evidence of previous exposure to CHIKV was observed in 37 individuals (2.8%). Sex, age, reported use of repellants, and bed net ownership and usage were not associated with CHIKV seropositivity. Our results showed the co-circulation of two other alphaviruses, ONNV and SFV, in Nouakchott in 30 (2.3%) individuals. This is the first study that documents the co-circulation of CHIKV, ONNV, and SFV in Mauritania, albeit at low prevalence. Surveillance and routine testing for alphaviruses and other arboviruses in symptomatic patients should be implemented in health facilities to assess the health burden associated with these viruses. Efforts should also be made to strengthen the vector control measures.

Keywords: ELISA; Mauritania; Nouakchott; O’nyong-nyong; Semliki Forest; alphavirus; arbovirus; chikungunya; neutralization; seroprevalence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Africa, Western
  • Chikungunya Fever* / epidemiology
  • Chikungunya virus*
  • Cross-Sectional Studies
  • Humans
  • Mauritania / epidemiology
  • O'nyong-nyong Virus
  • Seroepidemiologic Studies
  • Togaviridae
  • Urban Population

Grants and funding

This research received no external funding.